Note: Ingredients listed on restricted chemical lists
General Information
Revision date
2020-09-11
Product name
Zactran , Injectable solution
Product Synonyms
with API: Gamythromycin
1.2.1 Relevant identified uses
Pharmaceutical
1.2.2. Uses advised against
Safety Data Sheet only for the professional user on use
Emergency telephone
+1 703-527-3887 Chemtrec 24-hours
Icons in SDS
Company Information
company name
Boehringer Ing. Pharma GmbH & Co. KG
e-mail address of the competent person responsible for the Safety Data Sheet
EHS-Services@Boehringer-Ingelheim.com
GHS Information
Signal word
Danger
Hazard Codes
Hazard statements (CLP)
H317, H318
Hazard statements
Code
Statements
H317
May cause an allergic skin reaction
Section 2
CLP CLASSIFICATION
Serious eye damage , Category 1 H318: Causes serious eye damage. Skin sensitisation , Category 1 H317: May cause an allergic skin reaction.
2.2 Label elements
REGULATION (EC) No 1272/2008)
Signal word
Danger
Hazard statements
H317 May cause an allergic skin reaction. H318 Causes serious eye damage.
Prevention
P261 Avoid breathing dust/ fume/ gas/ mist/ vapours/ spray. P280 Wear protective gloves/ eye protection/ face protection.
Response
P305 + P351 + P338 + P310 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if pre- sent and easy to do. Continue rinsing. Immediately call a POISON CENTER/ doctor. P333 + P313 If skin irritation or rash occurs: Get medical advice/ attention. P362 + P364 Take off contaminated clothing and wash it before reuse.
Disposal
P501 Dispose of contents/ container to an approved waste disposal plant.
Hazardous Ingredients
Gamithromycin succinic acid 3-mercaptopropane-1,2-diol
Additional information
The following percentage of the mixture consists of ingredient(s) with unknown hazards to the aquatic environment: 55,45 %
2.3 Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumula- tive and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher. This drug is not subject to the labelling requirements under the Globally Harmonized System (GHS) The pharmacological effect of the medicament has to be considered (see package leaflet).
